Related Experiment Video
Updated: Jun 11, 2026

09:54
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
[Icteric hepatitis in a patient with non-Hodgkin's lymphoma treated by rituximab-based chemotherapy]
Nicola Coppola1, Addolorata Masiello, Gilda Tonziello
1Dipartimento di Medicina Pubblica, Clinica e Preventiva, Seconda Università di Napoli, Italy.
Le Infezioni in Medicina
|July 9, 2010
Abstract:
We report the case of a patient with non-Hodgkin's lymphoma who, during chemotherapy according to the r-CHOP schedule (rituximab-cyclophosphamide-doxorubicin-vincristine and prednisone), showed a hepatic flare with jaundice. Given the patient's state of asymptomatic carrier of HBsAg, we began a treatment of telbivudine (600 mg/die), resulting in a regression of hepatitis flare and negativization of HBV viraemia.